Navigation Links
Study Finds Treatment with Metreleptin Improved Diabetes and Lipid Control in Patients with Partial Lipodystrophy
Date:6/4/2011

SAN DIEGO, June 4, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a study that showed treatment with metreleptin, an investigational treatment that is an analog of the human hormone leptin, improved diabetes and lipid control in patients with partial lipodystrophy. Data from this study, the first findings from patients receiving metreleptin through Amylin's lipodystrophy expanded access program, were presented at the 93rd Annual Meeting and Expo of The Endocrine Society (ENDO) in Boston.

In this study, being conducted under a treatment IND authorized by the U.S. Food and Drug Administration (FDA), metreleptin is made available to patients with rare forms of lipodystrophy who have one or more metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream). This analysis focused on patients with partial lipodystrophy who had received treatment for at least six months. Treatment with metreleptin resulted in improvements from baseline in A1C (a measure of average blood sugar over three months) and triglycerides. Further, the majority of patients receiving metreleptin were able to reduce or discontinue treatment with pre-existing diabetes medications, including insulin.  

"We are committed to assisting patients who are living with lipodystrophy, a chronic and often debilitating disease that is not adequately managed by existing therapies," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals. "Our expanded access program enables us to provide patients with metreleptin while we continue working with the FDA to make the medicine more broadly available to patients with this rare disorder."

Results of this analysis were presented by Suma Amarnath, M.D., a member of the research team led by Elif Oral, M.D. during an or
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Questions Ability of Radiology Benefit Managers to Lower Costs
2. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
3. Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization
4. Tigris Pharmaceuticals Initiates Randomized Phase 2 Study of AFP-464 in ER-Positive Breast Cancer Patients
5. Robotic Prostatectomy Expert Dr. David Samadi on a High Impact Study Advocating Aggressive Early-Stage Prostate Cancer Treatment
6. All-Oral Combination Study with PSI-7977 for HCV Genotypes 1, 2 and 3 Initiated
7. Pivotal Phase 3 Study Published in The New England Journal of Medicine (NEJM) Finds Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer is Significantly Improved with ZYTIGA™ (abiraterone acetate)
8. Ardea Biosciences Provides Additional Results From a Phase 2b Study of Lesinurad in Combination With Allopurinol at the Annual European Congress of Rheumatology
9. InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
10. U-M Study: Children Dependent on Long-Term Mechanical Ventilation Require Longer, More Expensive Hospital Care
11. Use of TIGR® Matrix Surgical Mesh in Multi-Center Randomized Controlled TRAM Flap Study Passes 20 Patient Mark and Wins Praise from Participating Surgeons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and ... Interconnects and Packaging (EMIP) Division. "I am ... general management and business development experience, especially in the ... important contributions to the continued growth and success of ...
(Date:7/25/2014)... , July 25, 2014  Arena Pharmaceuticals, Inc. ... provide a corporate update and report second quarter 2014 ... on Friday, August 1, 2014. That same day, Arena ... a.m. Eastern Time (5:30 a.m. Pacific Time). ... 877.643.7155 for domestic callers and 914.495.8552 for international callers. ...
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... , , TOKYO ... Daiichi Sankyo Company, Limited (TSE: 4568), announced today that ... for edoxaban, its investigational oral Factor Xa inhibitor. This new ... and efficacy of edoxaban in reducing recurrent venous thromboembolic (VTE) ...
... , , SOMERSET, N.J. , Feb. ... trials in patients with acute low back pain (ALBP) who ... functionality and reduced disability after three days of treatment, as ... being presented this week at the 26th annual meeting of ...
Cached Medicine Technology:Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 2Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 3Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 4Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism 5SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 2SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 3SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 4SOMA 250 MG Shown To Significantly Improve Functionality and Reduce Disability in Patients With Low Back Pain in Three Days 5
(Date:7/27/2014)... 27, 2014 The constant expansion of ... in demand for enterprise video. Additional factors that have ... in areas such as corporate communication, learning and development, ... to all these factors the enterprise video market value ... to reach $35.57 billion in 2018 with a compound ...
(Date:7/27/2014)... 27, 2014 This is a ... Chinese Dutasteride (CAS 164656-23-9) industry. The report firstly ... including its classification, application and manufacturing technology. The ... of Dutasteride (CAS 164656-23-9) listing their product specification, ... The report further analyzes quantitatively 2009-2014 global and ...
(Date:7/27/2014)... 1-Butene is a colorless, combustible gas with ... can be manufactured either through the separation from crude ... Linear alpha olefin (alkene) 1-Butene is a versatile chemical ... important chemicals such as linear light density polyethylene (LLDP), ... 1-Butene market is extremely competitive. The market has several ...
(Date:7/27/2014)... July 27, 2014 As Tylenol ... continue to move forward in federal court, Bernstein ... questioning one of the benefits purportedly associated with ... The research, which appears in the The Lancet, ... all of whom were given either acetaminophen or ...
(Date:7/27/2014)... iFitDress.com, a well-known wedding dress manufacturer ... wedding gowns with sleeves . Furthermore, it has ... are now available with big discounts, from 20 to ... iFitDress.com is one of the big players in the ... new wedding gowns feature fine craftsmanship and charming looks. ...
Breaking Medicine News(10 mins):Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 2Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 3Health News:Global and Chinese Dutasteride Industry (CAS 164656-23-9) 2019 Forecasts in New Research Report at ReportsnReports.com 4Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America 1-Butene Market is Expected to Reach $794 million in 2018 - New Report by MicroMarket Monitor 4Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 2Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 3Health News:As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes Study Questioning Some Benefits Purportedly Associated with Acetaminophen 4Health News:Discounted Wedding Gowns With Sleeves Offered At iFitDress.com 2
... are discriminated against.,// ,There are signs in the UK ... bashful about it either, according to sources from the country’s ... to convince them that they should lose weight. The country’s ... of the country’s children are overweight, while 13% are obese. ...
... Russia will hold a beauty contest in which only HIV ... difference will be held in Russia on 1 December 2005, ... positive girls will participate.// The contest has been named ‘Miss ... attitude of the public with regard to the scourge, and ...
... both variant forms of a gene called CYP2A6, which are ... addiction.// The protein product of these genes is believed to ... ,The two identified gene forms are found to decrease ... more specifically found to account for slow processing of nicotine ...
... elderly heart failure patients in United States have better ... advantage over time.// ,Their study findings appear in ... ,Heart failure is the most common cause of ... countries. ,The authors compared process of care and ...
... patients with liver cancer. A cloud of confusion however ... who harbors a liver tumor that cannot be removed ... available for this group of patients. ,Thanks ... now suggested a novel plan for combating these tumors ...
... has found that besides being really harsh on the ears, ... Writing in the latest issue of the European Heart Journal ... mean an increased risk of heart attack. ,Researchers ... study between 1998 and 2001 in 32 hospitals in Berlin. ...
Cached Medicine News:Health News:Tendency To Smoke and Get Addicted Could Run In Families! 2Health News:Disparity In Survival Rates In US and Canadian heart Patients 2Health News:Novel Treatment Found To Prolong Survival Of Liver Cancer Patients 2Health News:Irritating Noise Increases Risk Of Heart Attacks 2
... detection and semi-quantitation of ... antigen in serum as ... diagnosis of autoimmune disease. ... performed either manually or ...
... for the detection and quantitation ... nuclear antigens (ENA) [RNP, Sm, ... in human serum. SS-A (Ro) ... in the diagnosis of SLE, ...
... Enzyme-linked immunosorbent assays for ... IgG antibodies to extractable nuclear ... human serum. SS-A (Ro) and ... the diagnosis of SLE, subacute ...
... Inc. ENA Screen ELISA test system is ... antibodies to extractable nuclear antigens (anti-ENA) in ... directional insert, this test system is capable ... such as those against Jo-1, Sm, Sm/RNP, ...
Medicine Products: